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The syndrome of transient epileptic amnesia:
a combined series of 115 cases and literature
review
John Baker,1 Sharon Savage,1,2 Fraser Milton,3 Christopher Butler,4,5,6 Narinder Kapur,7
John Hodges8 and Adam Zeman1
The term transient epileptic amnesia was coined in 1990 to describe a form of epilepsy causing predominantly amnestic seizures
which could be confused with episodes of Transient Global Amnesia. Subsequent descriptions have highlighted its association with
‘atypical’ forms of memory disturbance including accelerated long-term forgetting, disproportionate autobiographical amnesia and
topographical amnesia. However, this highly treatment-responsive condition remains under-recognized and undertreated. We de-
scribe the clinical and neuropsychological features in 65 consecutive cases of transient epileptic amnesia referred to our study, com-
paring these to our previous cohort of 50 patients and to those reported in 102 literature cases described since our 2008 review.
Findings in our two cohorts are substantially consistent: The onset of transient epileptic amnesia occurs at an average age of
62 years, giving rise to amnestic episodes at a frequency of around 1/month, typically lasting 15–30 min and often occurring on
waking. Amnesia is the only manifestation of epilepsy in 24% of patients; olfactory hallucinations occur in 43%, motor automa-
tisms in 41%, brief unresponsiveness in 39%. The majority of patients describe at least one of the atypical forms of memory dis-
turbance mentioned above; easily provoked tearfulness is a common accompanying feature. There is a male predominance (85:30).
Epileptiform changes were present in 35% of cases, while suspected causative magnetic resonance imaging abnormalities were
detected in only 5%. Seizures ceased with anticonvulsant treatment in 93% of cases. Some clinical features were detected more
commonly in the second series than the first, probably as a result of heightened awareness. Neuropsychological testing and com-
parison to two age and IQ-matched control groups (n¼ 24 and 22) revealed consistent findings across the two cohorts, namely ele-
vated mean IQ, preserved executive function, mild impairment at the group level on standard measures of memory, with additional
evidence for accelerated long-term forgetting and autobiographical amnesia, particularly affecting episodic recollection. Review of
the literature cases revealed broadly consistent features except that topographical amnesia, olfactory hallucinations and emotional-
ity have been reported rarely to date by other researchers. We conclude that transient epileptic amnesia is a distinctive syndrome of
late-onset limbic epilepsy of unknown cause, typically occurring in late middle age. It is an important, treatable cause of memory
loss in older people, often mistaken for dementia, cerebrovascular disease and functional amnesia. Its aetiology, the monthly
occurrence of seizures in some patients and the mechanisms and interrelationships of the interictal features—amnestic and affect-
ive—all warrant further study.
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Introduction
The term ‘transient epileptic amnesia’ (TEA) was coined
in 1990 to highlight the existence of a distinctive form of
epilepsy causing transient amnesic attacks.1,2 Their super-
ficial resemblance to the attacks occurring in ‘transient
global amnesia’ (TGA) warranted a related but contrast-
ing term. Hughlings-Jackson3 was probably the first au-
thor to raise the possibility that transient amnesia could
be the sole or most prominent manifestation of an epilep-
tic seizure, in his description of his physician–patient, Dr
Z. The suggestion was supported by case reports over
the following century, preceding the definition of TEA.4
Since then, further reports have defined an epilepsy syn-
drome characterized by recurrent brief attacks of transi-
ent amnesia, often occurring on waking, with onset
typically in middle age.5–7
The syndrome is of particular neuropsychological inter-
est as the amnestic seizures are frequently accompanied
by a distinctive group of persistent interictal memory
complaints: accelerated long-term forgetting (ALF), auto-
biographical amnesia (AbA) and topographical amnesia
(TopA).4,6,8 ALF is the excessively rapid loss of memory,
over extended intervals, of information that appears to
have been acquired and stored normally over standard
testing intervals of around half an hour. AbA refers to
the loss of memories for all or part of one’s past life:
This often comes to light when reviewing family photo-
graphs or reminiscing with friends and relations, and par-
ticularly affects the rich, ‘experiential’ or ‘autonoetic’
recall of salient personal events. TopA involves difficulty
in recollecting the layout of previously familiar environ-
ments, often when driving, and/or a failure to recognize
previously familiar landmarks and locations. While these
measurable memory problems have been described as
features in other types of epilepsy, and in other clinical
contexts, they occur particularly commonly in TEA as a
cohesive set of difficulties, probably reflecting the involve-
ment of relevant memory systems in this condition.
However, TEA remains a controversial disorder.
Through our project website (The Impairment of
Memory in Epilepsy (TIME Project) http://projects.exeter.
ac.uk/time/, we receive contacts from patients around the
world who have self-diagnosed, often following initial
misdiagnosis, or have found it difficult to locate a clin-
ician familiar with the disorder. Initial misdiagnoses, in
patients later shown to have TEA, have included TGA,
psychogenic amnesia, transient ischaemic amnesia, incipi-
ent dementia and sleep inertia. The TEA-associated inter-
ictal memory deficits are also under-recognized: clinicians
Graphical Abstract









niversity of Exeter user on 13 August 2021
continue to reassure concerned patients that their memory
is normal in the absence of tests of long-term retention
or remote memory, which can reveal otherwise undetect-
able but relevant memory impairments.9
This paper has two primary aims. First, to consolidate
the scientific description of TEA, we present a new series
of 65 patients with TEA [The impairment of memory in
epilepsy study: Phase 2 (‘TIME2’) case series] with whom
to compare the core clinical features identified from our
previous series of 50 patients [the impairment of memory
in epilepsy study: Phase 1 (‘TIME1’) case series].5 In
doing so, we seek to confirm previous observations
regarding demographic, seizure characteristics and interic-
tal features and then combine the cohorts to provide an
updated set of data based on this larger series of 115
patients. To determine whether these core clinical features
are then observed in other studies of TEA, we also re-
view relevant publications from other research groups,
post-dating our earlier review of the topic.4
Second, following the consolidation of all current evi-
dence regarding the description of TEA, we propose a
novel disease model, with discussion around key uncer-





Cases of TEA were recruited to the TIME (The
Impairment of Memory in Epilepsy) study, using Zeman
et al.7 diagnostic criteria:
(1) A history of recurrent witnessed episodes of transient
amnesia;
(2) Cognitive functions other than memory are intact dur-
ing typical episodes as observed by a reliable witness;
and
(3) Other evidence for a diagnosis of epilepsy. This can be
provided by any combination of:
a. Epileptiform abnormalities in electroencephalogram
(EEG),
b. The concurrent onset of other clinical features of an
epileptic seizure (e.g., lip-smacking and olfactory
hallucinations), or and
c. A clear-cut response to antiepileptic drugs.
Patients in TIME2 were either referred to the study via
a consultant neurologist (n¼ 53), or self-referred (n¼ 12)
after reviewing our project website (https://projects.exeter.
ac.uk/time/). In this study, we include only participants
referred to our study who were available for clinical as-
sessment and—in most cases—neuropsychological assess-
ment in the UK.
The study was approved by the Multicentre Research
Ethics Committee, United Kingdom (MREC 03/10/77).
All patients gave written, informed consent in accordance
with the Declaration of Helsinki.
Control participants
We draw on two sets of control data. For standard
neuropsychological measures, mood measures and for the
assessment of autobiographical memory, data previously
collected from the 24 healthy controls recruited in the
TIME1 series were used again for comparison in TIME2.
For measures of accelerated long-term forgetting, where
some adjustment in administration procedures occurred
between TIME1 and TIME2 (see Neuropsychological
Assessment below), a new cohort of controls was
recruited. This involved 22 age and IQ-matched healthy
adults from the Exeter and Oxford areas.
Clinical interview
Interviews were conducted by a member of the study
team. A detailed history was obtained from the patient
and at least one witness. A standardized data-collection
pro forma was used to collect information in relevant
domains (demographics, clinical features of the amnestic
attacks, interictal symptoms, past medical history, past
psychiatric history, epilepsy risk factors, current medica-
tions, family history). Medical case notes and correspond-
ence were reviewed.
Clinical investigations
EEG and magnetic resonance imaging (MRI) reports were
requested from the referring clinical teams.
Neuropsychological assessment
Standard measures
Participants were invited to complete a comprehensive
neuropsychological assessment. This involved the same
test battery as our original study, comprising measures
of: general intelligence (Wechsler Abbreviated Scale of
Intelligence-2 (WASI) subtest version10), anterograde
memory (immediate and 30-min delayed recall of prose
passage 1 from Wechsler Memory Scale-III11; copy and
30-min delayed recall of the Rey–Osterrieth complex fig-
ure (RCFT)12; the recognition memory test (RMT)13),
language (graded naming test)14 and executive function
(letter and category fluency).
Accelerated long-term forgetting
To take account of methodological recommendations
made elsewhere15 we modified the method used to assess
accelerated forgetting in our previous study.5 In this se-
cond cohort, the threshold for learning was lowered from
90% to 80%, with no minimum number of trials (to re-
move overlearning), and a verbal ‘wash-out task’ was
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included to reduce the impact of verbal working memory
on performance.
A list of 15 words (from the Rey Auditory Verbal
Learning Task) was presented orally over a maximum of
10 trials until at least 12 words (80% accuracy) could be
recalled within a given learning trial. Upon reaching this
criterion, participants were instructed to count backwards
out aloud from 100 for 40 s, to prevent rehearsal of
words. Recall of the words was assessed immediately fol-
lowing this distractor task, and at delays of 30 min and
at 1 week (via telephone). After this last free recall trial,
recognition memory was tested using the standard list of
30 words read aloud by the examiner (wherein the 15
targets are intermixed with 15 foils). The participant is
asked to indicate for each word whether it had been in
the original list or not. Scores were determined by the
correct identification of words on the original list (leading
to a maximum score of 15). Although participants were
not forewarned about the delayed probes, participants
were asked not to practice or write down the words be-
tween the face-to-face testing session and the telephone
follow-up.
Remote memory
Autobiographical memory was assessed using the modi-
fied autobiographical memory interview (MAMI), as in
our previous study.5 This semi-structured interview
requires participants to describe two events, relating to
specific topics (e.g. holidays, weddings, career changes,
car ownership and hobbies) from each decade of their
lives (from their 20s through to their current decade).
For each event described, participants answer 5 questions
designed to test their personal semantic memory (e.g.
what type of car did you own in your twenties?) and
then produce one detailed episodic memory (e.g. can you
recall one time when you broke down or took it to get
repaired/serviced?). Each episodic memory is scored out
of 5, based on the scheme described previously16 where a
score of 0 indicates a failure to recall a relevant memory
and 5 indicates successful retrieval of a specific episode
in which event details are described. This generates a per-
sonal semantic score (out of 10/decade) and an episodic
score (out of 10/decade).
Mood
Self-reported symptoms of depression or anxiety were
measured through the hospital anxiety and depression
scale.17
Statistical analysis
Statistical analysis of data obtained through neuropsycho-
logical testing was performed using IBM SPSS Statistics
25.0. Analyses of variance (ANOVA) were conducted to
compare groups’ performances (TIME1, TIME2 and con-
trols). Planned contrasts comparing: (i) TIME2
participants with controls and (ii) TIME1 participants
with TIME2 participants were included. We applied a
Bonferroni adjustment of alpha (0.05/11) ¼ 0.0045 to
correct for the number of neuropsychological measures
compared in each instance.
To examine any change in frequency of detected mem-
ory impairments across the two patient cohorts, a
Pearson’s chi-squared test was used to compare the num-
ber of cases identified in each patient cohort (where cases
of memory impairment were defined by performance 2 or
more standard deviations (SDs) below the control mean
on more than one neuropsychological test).
To investigate long-term anterograde memory perform-
ance, word list recall scores were compared between
TIME2 and a new, matched control group (see above)
via a repeated-measures ANOVA, with factors of partici-
pant group (TIME2 or control) and delay interval (40 s,
30 min and 1 week). The Huynh–Feldt correction for non-
sphericity was applied, where needed. Given the differen-
ces in procedure, no direct comparisons were made
between the TIME1 and TIME2 data sets.
Participants were entered into this analysis if they were
not impaired on standard measures of memory, had satis-
fied the learning criterion (80% recalled) and demon-
strated adequate retention over 30 min (recalling 8 or
more words, consistent with a performance >1.5 SD
from the mean in a normative study18) This was to en-
sure that accelerated long-term forgetting was not over-
estimated within the sample due to poorer initial encod-
ing and consolidation over shorter time periods.
To evaluate autobiographical memory in our second
cohort, the semantic and episodic memory scores per dec-
ade from the MAMI were analysed using repeated-meas-
ures ANOVA, with a between group factor of participant
group (TIME2 or control) and a within group factor of
decade (20s, 30s, 40s, 50s and most recent). For the one
participant whose current decade and epilepsy onset were
both in the 50s, data were not included in the analysis of
the ‘50s’ decade, but appeared under ‘most recent’ dec-
ade, to reflect acquired after the onset of TEA. To exam-
ine autobiographical memory performance for events that
occurred prior to the acute disturbances in memory due
to epilepsy onset, only patients with an age of TEA onset
>50 years were entered into this analysis. A separate
comparison of recent memory (from each individual’s
current decade) was also conducted.
Lastly, self-reported symptoms of anxiety and depres-
sion were analysed using ANOVA to compare TIME1,
TIME2 and healthy controls.
Literature search
We performed a literature search using the following key-
words: ‘transient epileptic amnesia’ in MEDLINE,
Embase and PsycINFO up to September 2018. Studies
published prior to 2008 were excluded as these had been
analysed in a previous review article.4 Titles and abstracts
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were reviewed and further hand-searching using reference
lists was performed to identify additional published
papers. Conference abstracts were not included in the
analysis, nor were articles published in a language other
than English.
The data that support the findings of this study are not
publicly available due to privacy and ethical restrictions.
Results
Clinical features in TIME2 patients
Demographics
A total of 65 patients (51 males, 14 females) were
recruited between January 2008 and April 2016. Mean
age at the onset of amnestic attacks was 61.4 years (SD
9.95; range, 26–77 years), and at entry into the study
was 65.6 years (SD 8.67; range, 39–81 years).
Diagnostic criteria
The grounds for the diagnosis of TEA in each case are
summarized in Fig. 1. Case-by-case details of diagnostic
criteria are provided in Supplementary Table 1.
TEA was the initial diagnosis in only 40% of cases
(26/65). Other initial diagnoses were: temporal lobe epi-
lepsy (18/65), TGA (10/65), transient cerebral ischemia/
stroke (6/65) and ‘psychogenic’ (5/65). The median delay
between first amnestic episode and diagnosis of TEA was
4 years (mean, 4.17; interquartile range, 3–5).
Seizure features
Duration, timing and frequency. Median attack duration was
15–30 min, with a wide variation (range <1 min to
days—see Supplementary Fig. 1). A total of 61/65
patients (94%) reported that at least some of their attacks
occurred on waking from sleep. However, only 5 patients
exclusively experienced seizures at this time. Median
frequency of attacks per annum prior to diagnosis was 12
(interquartile range 8–20). Median total number of
attacks experienced prior to diagnosis was 15 (interquar-
tile range 6–36).
Seizure types. Amnesia was the sole ictal manifestation in
13/65 (20%) of patients. In 33/65 (51%) brief unrespon-
siveness was reported in at least some attacks. 14/65
(22%) reported an epigastric aura. Olfactory hallucina-
tions were described in 29/65 (45%); the same percentage
reported motor automatisms, most commonly repetitive
chewing or swallowing movements (11/65, 17%). Tonic–
clonic seizures occurred in only 7/65 (11%) and were
typically isolated or rare events.
Ictal amnesia. A total of 30/65 (46%) patients had dense
ictal amnesia while the remaining 35/65 (54%) patients
were able, on some occasions at least, to ‘remember not
being able to remember’—i.e. had partial recall of their
transient amnestic episodes. Repetitive questioning dur-
ing episodes occurred in 41/65 (63%) cases.
Treatment. All patients were started on anticonvulsant medi-
cation, with 92% reporting complete cessation of attacks.
The most commonly used final medications were lamotri-
gine (31/65; 48%) followed by levetiracetam (14/65; 22%),
carbamazepine and sodium valproate (10/65 or 15% each).
Topiramate was used in 3 patients (3/65, 4.6%) and
zonisamide was used in one patient (1/65, 1.5%). Drug
changes were required in 24 patients (37%), either due
to inefficacy or side effects of the initial medication.
This included changes from carbamazepine in 12
patients, lamotrigine in 9 patients, sodium valproate in
8 patients, levetiracetam in 4 patients and phenytoin in
2 patients. Final median daily doses were: lamotrigine
150 mg (range 50–300 mg), levetiracetam 1000 mg
(500–3000 mg), carbamazepine 500 mg (300–1600 mg),
sodium valproate 900 mg (400–2400 mg), topiramate
100 mg (50–150 mg) and zonisamide 400 mg (400 mg).
At the time of interview, 59/65 patients (90.8%) were
on antiepileptic monotherapy, the remainder taking two
medications.
Interictal features
AbA. A total of 57 patients (88%) reported AbA, ranging
from patchy losses for the previous 1–2 years to loss of
memories up to 30 years in to the past. These forgotten
episodes were frequently noted in conversation with
friends and family and typically included shared experien-
ces such as weddings, holidays and birthdays.
ALF. A total of 48 patients (74%) reported ALF, either with-
out prompting or when asked if they had experienced
memories fading more quickly that they would typically
expect over hours to weeks.
TopA. A total of 47 patients (72%) reported TopA.
Olfaction. A total of 29 patients (45%) reported ictal olfac-






Figure 1 Frequency of cases meeting criteria for diagnosis
of TEA in TIME2 series patients.
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reduction in their sense of smell. Overall 34 patients
(52%) reported olfactory symptoms of some kind.
Emotional lability. A total of 26 patients (40%) reported a
state of emotional lability, principally involving a ten-
dency for sadness/tearfulness to be provoked by relatively
minor stimuli (24/26), and sometimes also a feeling of
increased irritability (4/26).
Investigations
MRI. Fifty-eight participants underwent a clinical MRI scan.
Clear abnormalities were detected in 4 patients: (i) high T2
signal in the right hippocampus; (ii) frontal encephalomala-
cia secondary to previous brain injury, (iii) slight T2 signal
change in both hippocampi and (iv) small cystic lesion in
the right caudate with small area of gliosis right lateral
ventricle and left posterior frontal lobe. A further two
patients were noted to have evidence of vascular disease
(mild microvascular ischaemia, past minor vascular event).
EEG. Sixty-one patients had undergone interictal EEG.
Overall, 22/61 (36%) were epileptiform, 17/61 (28%)
showed borderline abnormalities and 22/61 (36%) were
normal. Epileptiform discharges localized to the temporal
lobes, primarily, or solely, in the left hemisphere in
13/22, right-sided in 5/22 and bilateral in 4/22. Non-
specific abnormalities most often involved theta
activity, usually localized to the temporal lobes (11/17).
Other non-specific abnormalities included a single sharp
wave (n¼ 5) or a single sharp-slow complex (n¼ 2).
These borderline abnormal findings were focused bilat-
erally (7/17), on the right (7/17) or on the left (3/17)
(Supplementary Fig. 2).
Comparison with clinical features in TIME1 series
Table 1 presents the clinical features in the current series,
our previous series and the two series combined.
Demographics
Age at seizure onset and sex ratio were consistent be-
tween the two series, resulting in a mean onset age of
62 years, and a male predominance (overall 74% men).
Seizure features
Duration, timing, frequency. Seizure duration and frequency
were similar in the two series, with 12 brief attacks typic-
ally reported per year. Seizures on waking were reported
more often in TIME2, with an increase from 74% to
94% of cases (P¼ 0.003).
Seizure types. The frequency of repetitive questioning, ol-
factory hallucinations and motor automatisms were simi-
lar across the two patient groups (with overall frequency
ranging between 41% and 57% of patients). Pure amnes-
tic seizures and tonic–clonic seizures also occurred with
Table 1 Comparison of key features in TIME1 and TIME2
Core clinical features of TEA TEA 2007 (n 5 50) TEA 2017 (n 5 65) P-value TEA combined
(n 5 115)
Demographics
Mean age at onset (years) 62.1 (range 44–77) (SD 9.1) 61.4 (26–77) (SD 9.95) 0.872 61.7 (26–77)
Mean age at presentation (SD) 66 (SD 9) 65.6 (SD 8.67) 0.150 66.7
Sex distribution (M/F) 34/16 51/14 0.207 85/30
Seizure characteristics
Median number of attacks prior to diagnosis 10 (IQR 6–30) 15 (IQR 6–36) 0.263 12 (IQR 6–25)
Median frequency of attacks (per year) 12 (IQR 5–20) 12 (IQR 8–20) 0.953 12 (IQR 5–12)
Median attack duration 30–60 min (range <1 min
to days)
15–30 min (range <1 min
to days)
15–30 min (range <1 min
to days)
Cessation of attacks on AED (%) 96 91 0.294 93
Amnesia sole manifestation of a seizure (%) 28 20 0.318 24
Tonic–clonic seizures (%) 4 11 0.186 8
Some attacks on waking (%) 74 94 0.003* 85
Partial amnesia for attack (%) 56 54 0.840 55
Repetitive questioning (%) 50 63 0.164 57
Olfactory hallucinations (%) 42 45 0.749 43
Motor automatisms (%) 36 45 0.333 41
Brief unresponsiveness (%) 24 50 0.005* 39
Interictal features (%)
c/o autobiographical memory loss 70 88 0.017* 80
c/o accelerated forgetting 44 74 0.001* 61
c/o topographical memory loss 36 72 <0.001* 56
Emotionality 18 40 0.011* 30
Investigations (%)
Interictal epileptiform activity on EEG 37 33 0.656 31
Structural lesion on MRI 2 7 0.124 5
AED ¼ antiepileptic drug; AML ¼ autobiographical memory loss; c/o¼ complains of; EEG ¼ electroencephalogram; F ¼ female; IQR ¼ interquartile range; M ¼ male; MRI ¼ magnetic
resonance imaging.
*A significant difference between groups (P< 0.05). Cohorts compared using Pearson’s chi-square testing.
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similar frequency in the two series, in 24% and 8% of
patients respectively. There was an increase in reports of
brief episodes of unresponsiveness across the two cohorts,
half the cases reporting this in TIME2 compared to a
quarter of cases in TIME1.
Ictal amnesia. Partial recollection of attacks occurred in
around half of the patients in both groups.
Treatment. Over 90% of patients in both series reported
complete cessation of seizures following the initiation of
medication.
Interictal features
AbA, ALF, TopA. These specific interictal memory disturban-
ces were reported more often in TIME2 (all P< 0.05),
with almost twice as many patients reporting accelerated
forgetting (74%) and topographical amnesia (72% of
cases) as in TIME1.
Emotional lability. Increased emotionality was also reported
more often in TIME2 than it had been in TIME1
(P¼ 0.011).
Investigations
EEG and MRI abnormalities were seen with similar fre-
quency in the two series, with clear epileptiform activity
observed in approximately a third of cases, but structural
lesions occurring rarely (5% of patients overall).
Neuropsychology
Standard neuropsychology
Neuropsychological test results for patients in TIME1,
TIME2 and control participants are shown in Table 2.
While full assessments were conducted in 56 participants,
three were excluded from analysis given other neurologic-
al history which may have confounded test performance
(one because of significant head injury resulting in
structural changes evident on MRI; and two because of
evidence of past vascular events evident on MRI).
All three groups of participants demonstrated above
average intellectual ability. There were no significant
differences between TIME2 and healthy controls on lan-
guage or executive function tasks, however, significant
reductions were apparent on all of the anterograde mem-
ory tasks (P< 0.0045).
Accelerated long-term forgetting
ALF testing was completed per protocol in 36 of the
TIME2 participants (with an additional 15 participants
having either been administered a different version, or
having not completed the full protocol, and 2 participants
having not been administered the task). Thirteen were
excluded from analysis due to impaired performance on
standard tests of anterograde memory (delayed story re-
call). A further 4 failed to meet the word list learning cri-
terion, and an additional patient performed poorly at the
30-min interval. Nineteen TEA participants and 22 age
and IQ-matched healthy controls were therefore included,
subject to the same exclusions listed above (healthy con-
trol mean age ¼ 63.82, TIME2 subset mean age ¼
64.77 F[1, 41] ¼ 0.30, P ¼ 0.59; healthy control mean
IQ ¼ 116.86, TIME2 subset mean IQ ¼ 116.38, F[1,
41] ¼ 0.87, P ¼ 0.36). All participants completed be-
tween 3 and 10 learning trials, with no differences be-
tween the TEA and control groups on the total number
of learning trials (F[1, 40] ¼ 0.58, P ¼ 0.45), or average
final trial score (85%; F[1, 40] ¼ 0.01, P ¼ 0.93), sug-
gesting an equivalent performance during the learning
phase of the task.
As expected, recall performance declined over time for
both TEA and control participants (see Fig. 2 for mean
group results), with the lowest scores generated by the
TEA group at all delay intervals. Repeated-measures
ANOVA of recall performance confirmed a significant
main effect for group (F(1, 39] ¼ 10.46, P ¼ 0.002), a
Table 2 Neuropsychological test performance (mean and standard deviation)
Neuropsychological measure TIME2 (n 5 53) TIME1 (n 5 50) Controls (n 5 24)
Weschler abbreviated scale of intelligence (WASI) (2-subtest IQ) 115.7 (14.8) 118.3 (12.8) 120.0 (14.4)
Graded naming test (/30) 21.5 (4.8) 21.4 (5.1) 23.5 (4.2)
Controlled oral word association test (COWAT) (Letters F, A, S) 41.8 (13.6) 42.5 (13.9) 43.8 (11.4)
Animal fluency 19.5 (6.9) 19.3 (5.9) 22.0 (4.4)
Rey-Osterrieth complex figure tes (RCFT)—copy (/36) 33.5 (3.5)*,a 34.5 (3.1) 35.5 (1.1)
Logical memory (LM) (Story 1)—immediate (/25) 11.5 (4.1)**,b 14.0 (4.3) 15.9 (3.8)
LM (story 1)—delay (/25) 9.1 (4.7)** 11.7 (5.0)* 14.7 (3.8)
LM (Story 1)—recognition (/15) 12.1 (2.0)** 12.9 (1.4)* 13.6 (1.2)
RCFT—30 min delay (/36) 15.3 (5.9)**,a 15.0 (6.5)* 18.6 (6.1)
Recognition memory test (RMT)—words (/50) 43.3 (6.1)** 46.1 (4.7)* 48.3 (1.9)
RMT—faces (/50) 39.4 (5.3)** 40.7 (5.4)** 45.1 (2.9)
Healthy control participants from Butler et al.5 ANOVA conducted to compare groups’ performances. A Bonferroni adjustment of alpha (0.05/11) ¼ 0.0045 to correct for the
number of neuropsychological measures compared in each instance
aBased on a sample of n¼ 50.
bA significant difference P < 0.004 between TEA cohorts across TIME1 and TIME2.
*A significant difference P < 0.05 when compared with healthy controls.
**P< 0.0045.
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significant main effect for the delay interval (F(1.5,58.9)
¼ 153.73, P < 0.001), and, importantly, a significant
group  delay interaction (F(1.5,58.9) ¼ 6.29, P ¼
0.008). Planned contrasts to explore group differences
across the time intervals, showed that, while the TEA
and control participants did not differ significantly from
each other in their change shown between 40-s and
30-min recall (F(1,39) ¼ 0.03, P ¼ 0.86), the degree of
forgetting was greater in TEA participants compared to
controls when comparing the words recalled at the short
delay intervals (i.e. averaged across 40-s and 30-min re-
call intervals) and performance at the 7-day interval
(F(1,39) ¼ 7.74, P ¼ 0.008) (see Fig. 2).
Within the TEA group, 13 participants had reported
symptoms of ALF. To explore whether the group  delay
interaction was only evident within these participants,
additional separate analyses were run comparing control
performance firstly with TEA participants who did
(ALFþ) and did not (ALF) self-report ALF. As pre-
dicted, the interaction remained significant for ALFþ
patients versus healthy controls [F(1.53,66) ¼ 8.12, P ¼
0.002, with contrasts confirming that this effect was only
significant at the final level of delay (P ¼ 0.003) and not
at early intervals (P ¼ 0.97)] but was no longer signifi-
cant when comparing ALF patients with healthy con-
trols (F(1.57,40.92) ¼ 0.40, P ¼ 0.533, with a significant
main effect for delay, but no main effect for group).
Although it was not possible to compare recognition
memory scores of TEA and control participants, as con-
trol data were not collected, 8 of the 19 patients with
TEA performed at or below a score of 9, a level some-
times used to differentiate performance above chance. An
additional participant refused the task after being unable
to recall any words on free recall. Scores ranged from 7
to 14 out of 15 (mean ¼ 10.33, SD ¼ 2.38), with only
3 TEA participants scoring above 12.
Finally, to check for any associations among seizure
variables (total number of seizures and frequency of seiz-
ures prior to anti-convulsants) and long-term retention,
Spearman’s rho correlations were examined. There were
no significant results (1-week retention and total seizures
prior to anti-convulsants: rho ¼ 0.11, P ¼ 0.662;
1-week retention and seizure frequency prior to anti-con-
vulsants: rho ¼ 0.10, P ¼ 0.749). We note, however,
that patients were seizure free at the time of testing.
Autobiographical memory
The MAMI was conducted with 24 TEA participants
(17 M, 7 F) from TIME2 who met the criterion of TEA
onset from age 50 years onwards. As in TIME1, eligibility
also required participants to show adequate performance
(within 2 SDs of the mean of the healthy control group)
on standard anterograde memory tests (i.e. delayed story
recall). Individuals included did not differ on demograph-






















Word List Recall HC (n=22)
TEA with ALF (n=13)
TEA no ALF (n=6)
Figure 2 Mean word list recall performance of TEA patients and matched control participants over testing intervals
(TIME2). Repeated-measures ANOVA of recall performance confirmed a significant main effect for group (F(1,39) ¼ 10.46, P ¼ 0.002), a
significant main effect for the delay interval (F(1.5,58.9) ¼ 153.73, P < 0.001), and, importantly, a significant group  delay interaction
(F(1.5,58.9) ¼ 6.29, P ¼ 0.008). Planned contrasts to explore group differences across the time intervals showed that, while the TEA and
control participants did not differ significantly from each other in their change shown between 40-s and 30-min recall (F(1,39) ¼ 0.03, P ¼
0.86), the degree of forgetting was greater in TEA participants compared to controls when comparing the words recalled at the short delay
intervals (i.e. averaged across 40-s and 30-min recall intervals) and performance at the 7-day interval (F(1,39) ¼ 7.74, P ¼ 0.008).
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onset, time to diagnosis, yearly frequency of attacks) or
non-memory neuropsychological measures (IQ, naming,
verbal fluency, visuospatial) from those in TIME2 who
were not tested on the MAMI. Those included reported
slightly fewer symptoms of depression on the hospital
anxiety and depression scale, but this did not signify a
clinically meaningful difference as both groups were
within the normal limits. TEA participants were age
and IQ-matched with 18 healthy controls from TIME1
(TEA mean age ¼ 67.83, control mean age ¼ 68.17,
P ¼ 0.881; TEA mean IQ ¼ 120.08, control mean
IQ ¼ 121.50, P ¼ 0.735).
Figure 3 shows the mean scores by decade for the two







































Autobiographical memory - Episodic
TEA Control
Figure 3 Mean scores on the MAMI for TEA patients and matched control participants over decades. Error bars are SDs.
Repeated-measures ANOVA revealed a significant main effect for decade (F(2.68,104.61) ¼ 5.758, P ¼ 0.002). This followed a quadratic
function (F(1,39) ¼ 10.92, P ¼ 0.002) such that memories for the 20s and 50s were better recalled than for the middle decades. A significant
main effect was also found for group (F(1,39) ¼ 20.98, P < 0.001), with average personal semantic recall for controls slightly higher, at 9.58
out of 10, as compared with 8.53 out of 10 for TEA participants. However, no decade  group interaction (F(2.68,104.61) ¼ 2.65, P ¼ 0.059)
was observed, indicating that the pattern of performance of TEA participants, while lower, mirrored that of the controls. In the episodic
domain, a significant main effect arose for decade (F(3,117) ¼ 4.39, P ¼ 0.006), again with contrast testing confirming a quadratic relationship
where memories from the 20s and the 50s were better recalled that those from the middle periods (F(1,39) ¼ 11.95, P ¼ 0.001). The main
effect for group was also significant (F(1,39) ¼ 45.20, P < 0.001), with average episodic recall remaining high for controls at 9.14 out of 10, but
dropping to an average score of 6.23 out of 10 for TEA participants. The decade  group effect was not significant (F(3,117)¼ 0.87, P ¼ 0.457),
indicating that the overall pattern of performance across the decades was similar for the two groups.









niversity of Exeter user on 13 August 2021
the test, repeated-measures ANOVA revealed a significant
main effect for decade (F(2.68,104.61) ¼ 5.758, P ¼
0.002). This followed a quadratic function (F(1,39) ¼
10.92, P ¼ 0.002) such that memories for 20s and 50s
were better recalled than for the middle decades. A sig-
nificant main effect was also found for group (F(1,39) ¼
20.98, P < 0.001), with average personal semantic recall
for controls slightly higher, at 9.58 out of 10, as com-
pared with 8.53 out of 10 for TEA participants.
However, no decade x group interaction (F(2.68,104.61)
¼ 2.65, P ¼ 0.059) was observed, indicating that the
pattern of performance of TEA participants, while lower,
mirrored that of the controls. We note that the high
mean score of controls on our measure of personal se-
mantic memory raises the possibility of a ceiling effect,
which could lead to some underestimation of the corre-
sponding deficit among patients
Similar but more striking results were found in the epi-
sodic domain. A significant main effect arose for decade
(F(3,117) ¼ 4.39, P ¼ 0.006), again with contrast testing
confirming a quadratic relationship where memories from
the 20s and the 50s were better recalled that those from
the middle periods (F(1,39) ¼ 11.95, P ¼ 0.001). The
main effect for group was also significant (F(1,39) ¼
45.20, P < 0.001), with average episodic recall remaining
high for controls at 9.14 out of 10, but dropping to an
average score of 6.23 out of 10 for TEA participants.
The decade x group effect was not significant (F(3,117)
¼ 0.87, P ¼ 0.457), indicating that the overall pattern
of performance across the decades was similar for the
two groups.
To determine the proportion of TEA participants who
at an individual level showed impaired performances at
each decade, cut-off scores were calculated using the
threshold of 2 SDs below the control mean. Proportions
varied from 38% of patients (for the 30s decade) up to
79% (for the 50s decade), with only two participants
(13%) not classified as impaired on any of the examined
decades. Thus, impairments were highly prevalent and
observed across the lifespan.
Finally, to check for any associations among seizure
variables (total number of seizures and frequency of seiz-
ures prior to anti-convulsants) with overall autobiograph-
ical memory performance, Spearman’s rho correlations
were examined. There was no significant relationship
between average episodic memory performance on the
MAMI and frequency of seizures prior to anti-convulsant
medication (rho ¼ 0.11, P ¼ 0.624), but there was a
significant, negative association between average episodic
MAMI score and total number of attacks (rho ¼ 0.41,
P ¼ 0.047), indicating that those who had experienced
more seizures showed poorer autobiographical memory.
Mood
Participants reported relatively few symptoms of anxiety
or depression (see Table 2). While no statistical differen-
ces were observed when comparing mean depression
scores from healthy controls with TIME2 participants
(t (68.78) ¼ 1.538, P¼ 0.129) there was a statistical
difference regarding reported symptoms of anxiety
(t (65.338) ¼ 2.219, P¼ 0.03). This numerical
difference, however, is not clinically significant as both
groups reported mean levels below the standard clinical
cut-offs (<8).
Comparison with neuropsychological and mood
features in TIME1 series
Performance of TIME1 and TIME2 cohorts was similar
(all P > 0.16) on standard neuropsychological tests
except that the TIME2 group performed more poorly on
the immediate recall of a short story (t (101) ¼ 3.05,
P ¼ 0.003). At the individual level, a third of TIME2
participants (34%) showed significant memory impair-
ment (>2 SDs below the control mean on 2 or more
memory tests). Although a slightly higher number than
observed in the TIME1 cohort (28%), the difference
was not significant (n¼ 103; v2 ¼ 0.427, P ¼ 0.531). No
differences were observed in self-reported symptoms of
anxiety (P ¼ 0.159) and depression (P ¼ 0.216). Thus
the findings of standard neuropsychological tests and
mood of TIME1 appeared largely replicated in this se-
cond cohort.
The findings with respect to ALF and AbA are also
broadly similar in the two groups. Subtle differences in
test administration and patient selection mean that the
results are not exactly comparable, but there was clear
evidence in both study groups of (i) an anterograde mem-
ory impairment that—in some cases—became apparent
only at longer than standard delays and (ii) an autobio-
graphical memory impairment affecting memory for both
semantic and episodic details, the latter more severely,
both occurring in participants with normal memory
performance on standard tests.
Literature review
Using the search term ‘Transient Epileptic Amnesia’, we
identified 322 publications between 2008 and 2018, after
deduplication (Supplementary Fig. 3). The results were fil-
tered to include only case series and case reports of novel
cases of TEA: this yielded in total, 102 patients with
TEA from 23 studies, which are summarized in Table 3,
excluding the cases from our previous and current stud-
ies. All cases satisfied the Zeman et al.7 criteria for TEA.
Clinical features
Demographics
Summing across these studies, the sex ratio was equal
(males 51, females 51), though three of the four larger
series reported a male preponderance.6,19,20 The mean
age of onset for TEA has been reported as 59, 67.2 and
66.6 years in the three larger series providing this infor-
mation, with onset age ranging from 35 to 85 years.
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The reported interval between symptom onset and diag-
nosis ranges from around 6 months to 6.2 years.
Diagnostic criteria
Seizure features. Duration. The majority of reported episodes
fall between a few minutes and 1 h, but there is exten-
sive variation with seizure episodes lasting from <1
min21 up to 24 h.22
Timing. A total of 13/23 (57%) studies included in this re-
view describe episodes of TEA occurring on waking in
27/60 (45%) patients.
Frequency. The frequency of TEA attacks ranges from sev-
eral times per week23 to less than once per year.24
Comparable data are available for 15/23 studies listed
above (46/114 cases). In this group, 6/46 (13%) report at
least one seizure per week, 17/46 (37%) report seizures
at least once per month but less than weekly and 23/46
(50%) describe less than one seizure per month.
Seizure types. Pure amnestic seizures are described in be-
tween 17%6 and 64%19 of patients. Brief unresponsive-
ness is reported in a total of 9/23 studies. A total of 12/
51 (23.5%) cases presented by these studies describe this
phenomenon. An epigastric aura is described in three
studies25–27 and orofacial automatisms in four.24–27
Generalized tonic–clonic seizures are uncommon [10% in
Mosbah,6 9% in Lapenta19]. In one case,28 persistent gen-
eralized tonic–clonic seizures were resistant to anti-epileptic
treatment leading to a temporal lobectomy.
Treatment. Patients with TEA respond well to treatment
with anti-epileptic medication. 94/96 cases (97.9%) in
whom the response to anti-epileptic treatment was
reported describe a reduction in the number of seizures
following initiation of medication. In 59 of these patients,
this is documented as being complete seizure cessation,
and in 12, this reduction is described as partial (>50%
reduction in seizures). Ramanan et al.20 states that 18/19
patients improved—although it is not clear whether this
represents a partial or complete improvement.
Interictal features. The interictal features described in TEA
have not been routinely assessed in either case studies or
case series of TEA patients and are therefore not as thor-
oughly described. Findings in studies where these features
have been investigated are described below.
AbA. A total of 14/23 studies included in this review de-
scribe interictal autobiographical memory impairments.
Mosbah et al.6 report that retrograde memory loss is
greater for the episodic than the semantic component of
autobiographical memory. Recent memories were espe-
cially severely affected, with measurable improvement in
autobiographical memory for events from the past five
years following treatment.6
ALF. A total of 10/23 studies describe the presence of ALF
in TEA, in 25 patients. In studies with multiple patients,
this feature was described in 16/30 (53%),6 4/19 (21%)20
1/3 (33%)26,29 or 1/2 (50%),24 giving a total of 22/54
(40.1%).
TopA. TopA is described in only 2/23 studies (2 patients);
described as either ‘a tendency to lose her way even in
familiar locations’30 or simply as ‘topographical am-
nesia’.26 None of these studies measured topographical
memory formally examined using neuropsychological
tests.
Olfaction. A decreased sense of smell, occurring in the set-
ting of TEA was described in only 1 study (1 patient).31
One of the three cases described by Ioannidis et al.26 fea-
tures reports of ‘strange and bad smells’ as an element of
seizure episodes.
Emotionality. Two of the 23 studies describe a clear change
in the emotional character of their patients with TEA. In
one case, this change was becoming angry and short-tem-
pered,31 and in the other low mood and depression was
reported.25
Investigations. EEG. The rate of EEG abnormalities reported
in published case series has exceeded 50% (57%6 and
64%19). EEG abnormalities have also been common in
TEA case reports, most often occurring in the right tem-
poral or fronto-temporal leads,21,23,26,32 although abnor-
malities are also frequently found on the left28,33 and
bilaterally.34,35
MRI. In the largest TEA case series, the majority of partici-
pants have normal MRI scans (15/19,20 21/30,6 11/1522).
Of the 98 cases where MRI results were reported, 73.5%
were normal. Where MRI abnormalities have been
described, these have most commonly involved the tem-
poral lobes (18/26), with findings including mesial tem-
poral lobe signal abnormalities,19 right temporal
cavernous angioma,26 a small hyperintense lesion in right
hippocampus,36 restricted diffusion left hippocampus20
and enlarged hippocampal volume with loss of architec-
ture and increased hippocampal tail signal.33 Extra-tem-
poral abnormalities have included bifrontal post-
traumatic change,22 right parietal lobe meningioma6 and
a right anterior choroidal aneurysm.26
Discussion
The substantial series of patients described here, com-
bined with those in the literature review, support the ex-
istence of a treatment-responsive epilepsy syndrome
characterized by amnestic seizures, often occurring at
roughly monthly intervals, typically lasting for 15–
30 min, frequently manifesting on waking, and with onset
in middle age; a high frequency of interictal memory
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deficits, especially ALF and AbA, and—principally in our
case series—both ictal and interictal olfactory disturbance
with a tendency to emotional lability, specifically easily
provoked tearfulness. We will discuss in turn (i) whether
TEA should be regarded as an epilepsy syndrome, (ii) the
neuropsychological and neurobiological bases of the
prominent associated interictal memory disturbance and
(iii) a model designed to capture current understanding of
the condition and to identify key unanswered questions
for future research.
Is TEA an epilepsy syndrome?
There are compelling grounds for concluding that epi-
lepsy is the underlying cause of the disorder described
here: our diagnostic criteria require the presence of one
or more indicative features, specifically the detection of
epileptiform change on EEG, the occurrence of other clin-
ical phenomena suggestive of epilepsy, such as paroxys-
mal alteration of awareness or olfactory hallucinations,
and/or a clear-cut response to anticonvulsant drugs.
While opportunities to record EEG during an amnestic
episode are exceptional, such recordings indicate that
transient amnesia can occur both as an ictal and as an
immediately postictal manifestation.37
If the diagnosis of epilepsy is accepted in these cases,
do they belong to a distinctive epilepsy ‘syndrome’?
Epilepsy syndromes involve a ‘complex of signs and
symptoms that define a unique epilepsy condition’; the
complex should involve ‘more than just the seizure type’
but is distinct from an ‘epilepsy disease’, a condition with
a ‘single, specific, well-defined aetiology’.38 TEA precisely
satisfies this definition, given its distinctive demographic
features, ictal characteristics and interictal manifestations.
As its aetiology is varied, it is not an ‘epilepsy disease’.
In this section, we will consider some potential objections
to this view, in particular inconsistencies between the fea-
tures reported in the existing literature, the existence of
atypical cases and the ‘grey zone’ between TEA and other
forms of temporal lobe or limbic epilepsy. The question
of aetiology is considered further in section (iii).
While our two consecutive series of patients with TEA
display marked commonalities, in demographic features
and ictal characteristics, they differ with respect to the
reported frequency of episodes on waking, interictal
memory disturbance and emotional lability. In each case,
the frequency of these features was higher in TIME2
than in TIME1. While we attempted to gather clinical
data in a consistent fashion over time, we suspect that
the apparent increase in the frequency of these features
reflects increased vigilance, stimulated by our initial find-
ings, rather than any true difference between the patient
groups. However, whether or not this is the case, these
modest quantitative differences between the two series do
not undermine the key elements of the syndrome, out-
lined above.
The 115 patients described from our centre broadly re-
semble those reported from other centres in most
respects, in particular, age of onset and seizure character-
istics. The interictal neuropsychological features of TEA
have been reported less frequently in other reports than
in ours, but both AbA and ALF have been described re-
peatedly. Olfactory disturbance and emotional lability are
much more common in our series than in other reports:
Whether this reflects a true difference, or a difference in
ascertainment, is unclear.
Some cases in our current series are atypical with re-
spect to age, length of amnesic episode, treatment resist-
ance; one additional case reported provocation of
amnesic episodes by exertion. Two cases (305, 340) pre-
sented below the age of 30, more than three SDs below
the mean age at presentation. Case 305 satisfied all three
diagnostic criteria, with attacks of typical duration; case
340 satisfied one criterion (clear-cut treatment response)
with longer than usual attacks (1–2 h); both had attacks
on waking. Case 305 had experienced 26 episodes, case
340 five episodes. 4 patients (241, 383, 257 and 346)
had ‘TGA-like’ episodes of amnesia lasting >2 h: Three
of these patients satisfied two criteria each (treatment re-
sponse and the occurrence of other suggestive features,
olfactory hallucinations in two cases, unresponsiveness in
one), while case 257 satisfied one criterion (treatment re-
sponse). All four patients had experienced >10 episodes,
and three of the four described episodes on awakening.
All four were in their fifties. Five patients described an
incomplete response to treatment (243, 360, 365, 356
and 261). Three (243, 360, 365) satisfied three criteria,
while case 356 satisfied two (automatisms/unresponsive-
ness and treatment response, albeit partial) and case 261
satisfied one (clear-cut but incomplete treatment re-
sponse). All had experienced frequent events of typical
duration (<1 h), some occurring on waking. Three
patients were in their sixties, two in their fifties. One pa-
tient, an overseas patient assessed in the UK but not
included in the current series, described episodes of typ-
ical duration, occurring at roughly monthly intervals,
often on waking, and gave a clear description of precipi-
tation of episodes by exertion, a feature more often asso-
ciated with TGA; some episodes were accompanied by
olfactory hallucinations and video-telemetry confirmed
the diagnosis of epilepsy. Thus, these atypical features
generally occurred singly, in patients whose characteristics
were otherwise typical for TEA, with no suggestion of
distinct subgroups or likely alternative diagnoses.
Finally, in some patients, the clinical phenotype falls in
a grey zone between ‘typical’ temporal lobe or limbic epi-
lepsy, and TEA. For example, patients with focal seizures
with impaired awareness sometimes exhibit a period of
prominent postictal amnesia. There is also a group of
patients with temporal lobe epilepsy who present with
notable interictal memory disturbance of the kind associ-
ated with TEA, accompanied by subtle seizures, but who
never have amnestic events of the kind required for a
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diagnosis of TEA. The term ‘Epileptic Amnesic
Syndrome’ has been proposed to accommodate patients
with temporal lobe epilepsy (TLE) accompanied by such
interictal memory disturbance regardless of whether they
do or do not also have amnestic seizures.21,39–41 The fea-
tures of such borderline cases do not, however, call into
question the existence of the core syndrome of TEA.
Thus, TEA is a distinctive epilepsy syndrome, with sub-
stantially consistent features across the two series of
patients described from our centre and in recent reports
from other centres. The relatively minor inconsistencies
between our two series are likely to be explained by
heightened awareness of the clinical features by the time
we studied our second series. The existence of ‘atypical’
and ‘grey’ cases indicates that there are areas of overlap
between TEA and other related epileptic conditions but
does not invalidate the proposal that TEA is a distinctive
epilepsy syndrome.
The nature of the interictal
memory disturbance in TEA
The majority of patients with TEA describe characteristic
symptoms of interictal memory disturbance, in particular
symptoms of ALF, AbA and TopA. These are often the
most prominent and sometime the earliest symptoms of
TEA.6,9,21,42 As only ALF and AbA have been studied in
detail in the context of TEA we will focus on these here.
These phenomena are now established clinical entities
with operational definitions. Some individuals with
TEA—and other conditions—who perform within normal
limits on standard measures of memory nevertheless have
measurable evidence of ALF and/or AbA in the presence of
corresponding symptoms. There is, however, continuing un-
certainty about the pathophysiology of these phenomena,
specifically regarding which phase of memory processing is
perturbed (see Fig. 4) and whether the underlying cause is
a disturbance of function or of structure.
In the case of ALF, the presence of memory impairment
at extended intervals in patients with apparently normal
learning, and intact early recall, suggests an impairment
of memory consolidation. This interpretation is supported
by examples of patients with impeccable performance on
anterograde tests at standard intervals who nonetheless
show marked accelerated long-term forgetting.37,42–45
Existing evidence indicates that ALF is first detectable
within hours of learning,46 and that it occurs predomin-
antly during wakefulness rather than sleep, perhaps hint-
ing at an increased sensitivity to retroactive
interference.46,47 However, there is also evidence that
patients with TEA show early forgetting, over standard
intervals, on recognition tests using visual materials,48,49
and some work in patients with TLE has suggested that
ALF flows from an impairment of memory acquisition.50
Thus, it remains controversial whether ALF reflects a
true impairment of memory consolidation or rather the
increasing sensitivity of memory tests at longer intervals
to impairments present from, or very close to, the point
of memory acquisition. We have previously suggested
that this may be, in part, a false dichotomy, as such
impairments will often coexist and interact.45,51
There is also uncertainty over the relative importance
of reversible functional factors, particularly ictal or inter-
ictal discharges versus structural factors in the causation
of ALF. Studies—predominantly in patients with TLE—
identifying a positive correlation between seizure fre-
quency and ALF,52–54 interictal discharge frequency and
ALF,53,55 and reduction of ALF by anticonvulsant treat-
ment56,57 and epilepsy surgery58 argue for the importance
of functional disturbance. The apparent reversibility of
ALF in some cases of TEA also points to a modifiable
cause.59 However, other studies have failed to identify
such relationships.42,60,61 Moreover, ALF has recently
been reported in patients with pre-symptomatic genetical-
ly determined Alzheimer’s disease62,63 and in children fol-
lowing head injury,64 suggesting that epileptiform brain
activity is probably not required for its occurrence.
Conversely, Butler et al37,65 found no correlation between
volumes of limbic structures and the severity of ALF,
arguing against a straightforward structural explanation
of ALF in TEA. Thus, just as impairment of both early
and later phases of memory processing are likely to con-
tribute to ALF, so it seems likely that both functional
and structural factors may be relevant, though the
evidence in TEA somewhat favours the importance of
functional disturbance. In a detailed single case study, the
resolution of ALF on withdrawal of the inciting agent—







Figure 4 Mechanisms of amnesia occurring in TEA. The
mechanisms of the three well-studied forms of amnesia occurring in
TEA in relation to the key stages of memory processing: Episodes
of ictal amnesia (‘TEA’) result from impairment of memory
encoding, retrieval or, often, both; ALF is due to an impairment of
consolidation processes, with a possible contribution from an
encoding impairment; the AbA probably results from memory
degradation or erasure, in the case of remote memories, but loss of
access, impairing retrieval and ALF, affecting consolidation, can also
play a part.
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With respect to the AbA associated with TEA, detailed
case studies indicate that TEA can erase or render in-
accessible previously detailed autobiographical memo-
ries.9,45,66 This points to a disorder of storage, or
possibly retrieval, although even rich retrieval cues failed
to elicit recollection in these cases, arguing that in general
storage is the more likely locus of pathology. We have,
however, previously reported one patient who unexpect-
edly ‘recovered’ memories indicating that retrieval failure
is, at least sometimes, the explanation for AbA in this
condition.67 Finally, individuals with ALF would be
expected to develop a degree of AbA over time for events
occurring after the onset of ALF: The ‘disappearance’ of
initially detailed memories, of the kind predicted by this
hypothesis have been documented in the cases of CS45
and MB.9 Mosbah et al.6 reported an improvement in
autobiographical recall for recent events following treat-
ment, in keeping with this possibility; Savage et al.68 re-
port a similar improvement in patient CS. Thus it is
likely that AbA in TEA can reflect disorders of several
stages of memory processing, including consolidation,
storage and retrieval. Our working hypothesis is that the
primary mechanisms of AbA in TEA, particularly in cases
with temporally extensive memory loss, is degradation of
stored engrams. One further possibility is worth consider-
ing, though there is at present no relevant evidence: That
the AbA of TEA is due to a problem with reconsolida-
tion.69 This could account for the close association be-
tween ALF and AbA.
Anecdotal evidence points to a role for epileptic activity
in the genesis of TEA-related AbA. This idea receives
some support from the significant negative correlation,
reported above, between total number of seizures and the
episodic memory score in the current (TIME2) patient
series. The probable though controversial association be-
tween electroconvulsive therapy, which produces iatrogen-
ic seizures and AbA,70 is also in keeping with the
hypothesis that TEA-related AbA is at least partly the
outcome of epileptic activity propagating through the
autobiographical memory network, resetting the synaptic
weights on which episodic autobiographical memories are
likely to depend. Although there is evidence in other con-
texts that structural brain damage can produce AbA,9,71
to date there is no evidence of any correlation between
volume loss in limbic structures and AbA in patients with
TEA. Thus, the available evidence favours a role for epi-
leptiform activity in the causation of AbA in TEA, with a
possible, but so far unquantified, contribution from struc-
tural factors.
Cognitive deficits occurring in epilepsy are sometimes
caused by drug treatment and by mood disturbance.
However, given that both ALF and AbA can be detected
in patients with TEA prior to treatment6 and that there
is no evidence for an elevated rate of mood disturbance
in the majority of patients5,6; this series), neither explan-
ation is likely here.
In summary, ALF and AbA, both common interictal
features of TEA, reflect disorders of several stages of
memory processing, affecting acquisition and consolida-
tion in the case of ALF, storage and retrieval in the case
of AbA for remote memories (with a contribution from
ALF in the case of Aba for post-onset memories).
Current evidence favours a predominant role for neuro-
physiological factors in causing these phenomena in TEA,
though structural factors are undoubtedly relevant in
other contexts, and may also play some role in TEA.
A model of TEA
The aim of this section is to summarize current know-
ledge of TEA, identify unanswered questions and propose
testable hypotheses regarding the underling mechanisms
(Fig. 5).
Aetiology
The majority of cases of TEA are of unknown aetiology,
but its typical occurrence in middle aged people, with a
probable male predominance, points to an age-related
susceptibility and the possible relevance of hormonal fac-
tors. Although TGA is unlikely to result from epilepsy in
the majority of cases, the similarity in the ages of patients
affected by TGA and TEA suggests that common age-
related factors underlie both conditions. Rare
Figure 5 A model of TEA. Yellow text summarizes
demographic and aetiological factors; the central circle
highlights the limbic regions likely to contain the seizure focus; red
text summarizes the key clinical features, which also include
interictal memory disturbance, ALF (black) and AbA (white). The
numbers refer to possible mechanisms for ALF and AbA (see main
text for further discussion); the neocortex interacts with limbic
regions in memory processing. HC ¼ hippocampus; LEs ¼ life
events; OFC ¼ orbitofrontal cortex; PHC ¼ parahippocampal
cortices (including perirhinal cortex).
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symptomatic (lesional) cases of TEA are described and
discussed further below. We have recently reported a case
of TEA occurring secondary to NMDAR antibody medi-
ated encephalitis.68 Transient amnesia has been described
as a seizure type among patients with Alzheimer’s disease,
but we have not seen the typical syndrome of TEA
occurring in the context of Alzheimer’s disease.72,73 The
significance of the high IQ of the patients in our series is
uncertain, but we suspect it reflects the need for an ar-
ticulate description of confusing symptoms in the diagno-
sis of TEA. The possibility that vascular risk factors may
predispose to TEA was raised tentatively in a previous
case control study, with associations—on the borderline
of significance after correction for multiple compari-
sons—between TEA and cardiac arrhythmia, valve disease
and arterial aneurysm.74 Some patients with TEA have
an initial episode closely resembling TGA, posing the
question of whether TGA can sometimes lead to TEA.
Mosbah et al.6 noted a high frequency of depression and
adverse life events preceding the onset of TEA in their
cases: We have also encountered individual cases in
which mood disorder and life events are plausible trig-
gers, but these relationships require further systematic
study before firm conclusions can be drawn.
Seizure source
Manual and automated measurement of brain structures
in TEA has revealed mild atrophy of limbic regions,
namely bilateral straight gyrus, medial orbital gyrus,
hippocampus and right perirhinal cortex.37,65 In the mi-
nority of cases with a likely structural cause for TEA, the
causative lesion usually lies within or close to this group
of regions. In a single case study with radiological local-
ization, an exacerbation of TEA was associated with
swelling and high signal in the left hippocampus with
hypermetabolism in the same region on a fluorodeoxyglu-
cose PET scan which resolved with symptom improve-
ment.37 This patient went on to develop left hippocampal
atrophy. In cases with epileptiform interictal EEGs, or
ictal recordings, the discharges are temporal or fronto-
temporal, in keeping with the localization suggested by
brain imaging. Therefore, TEA can be regarded as a
form of temporal lobe epilepsy. However, as some cases
may originate in extra-temporal (e.g. inferior-orbital)
areas, it may be more correct to describe TEA as a sub-
type of limbic epilepsy.
Seizure characteristics
The amnesic episodes in TEA, which typically last around
half an hour, are unusually prolonged for epileptic seiz-
ures: We discuss their mechanism further below. Their
occurrence on waking is in keeping with a medial tem-
poral seizure source.75,76 Sleep EEG recordings can be
useful in diagnosis.6 The high frequency of monthly epi-
sodes is a striking and puzzling feature, hinting at some
underlying process with a similar time course involving
limbic cortices, but cyclical epilepsy is described in other
contexts.77–79 Olfactory hallucinations, sometimes pro-
longed and both subjective and objective alterations in ol-
faction, are common in TEA, at least in our experience,
and can provide a diagnostic clue. Amnesia occurs as the
sole ictal manifestation in around one quarter of cases of
TEA; other manifestations include olfactory hallucina-
tions, brief loss of awareness, automatisms and, rarely,
tonic–clonic seizures.
Seizure mechanism
Surface EEG recording during an amnesic attack was per-
formed in nine literature cases and one TIME1 case.4 All
recordings showed seizure activity, which in 8/10 cases
involved both temporal lobes and in the others remained
unilateral (one left sided and one right sided). Amnesia
was observed as an ictal phenomenon in six cases and as
postictal in four cases. In some ictal cases the underlying
seizure activity was prolonged,80 accounting for the cor-
respondingly prolonged amnesic state This suggests that
the amnesia occurring in episodes of TEA can occur both
as true ictal manifestations and as postictal phenomenon,
a ‘Todd’s paresis’ of memory. The precise temporal rela-
tionship between seizure onset and offset and the associ-
ated amnesia is, however, uncertain in the majority of
cases of TEA.
Emotional lability
We noted a characteristic form of emotional lability in
18% of our first series of patients, and in 40% of the
current series, a result, we suspect, of greater awareness
of this feature. This typically involves a heightened emo-
tional reactivity to poignant but relatively minor trig-
gers, such as a story or tune on radio or TV, or a
social encounter, often leading to unexpected tearful-
ness. A strikingly similar phenomenon has been
described recently among patients with limbic
encephalitis.81
Interictal memory disturbance
Figure 5 indicates potential mechanisms for ALF and
AbA. For ALF, ‘1’ refers to the possibility that a focal
pathology or disturbance in function of limbic
structures, most likely the hippocampus, disrupts
memory acquisition and/or consolidation. The pathology
could be integral to the underlying cause of the epilepsy,
a structural result of the epilepsy or reflect an
adaptation to the epilepsy: Taking our observation that
an intrathecal-administered Gamma aminobutyric acid
(GABA) receptor B agonist, Baclofen, can cause ALF,45
together with evidence that experimental epilepsy can
induce compensatory inhibitory mechanisms,82 we hy-
pothesize that excessive inhibition within the medial
temporal lobe memory system may be a mechanism of
ALF.83 Second (‘2’), disruption of the normal dialogue
between the medial temporal lobe and the neocortex,
required for the consolidation of recently acquired mem-
ories could play a role.51 Finally (‘3’)—and not to the
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exclusion of 1 and/or 2—ictal and interictal discharges
may disrupt memory processing.
In the case of AbA, structural pathology (‘1’) in the
medial temporal lobe, perhaps detectable using high field
MRI imaging,71,84,85 could underlie the depletion of auto-
biographical memories that occurs in TEA, in keeping
with the ‘multiple (hippocampal) trace’ model of remote
memory.86 Ictal or interictal discharges may delete (‘2’)
or render inaccessible (‘3’) engrams in the medial tem-
poral lobe (‘1’) or neocortex (‘4’).
Conclusion
The growing world literature on TEA included 94 cases
at the time of our previous review in 2008, among them
50 from our first series; in the current paper we report a
further 65 patients studied at our centre and 114 cases
from elsewhere reported since 2008. This now substantial
patient cohort indicates that TEA is a distinctive form of
late-onset limbic epilepsy. It gives rise to recurrent epi-
sodes of transient amnesia, typically lasting for around
30 min, often on waking, frequently occurring at intervals
of around one month. The predominantly ‘memory-
related’ presentation of TEA often leads to referral to
memory clinics or for psychiatric assessment; diagnosis is
frequently mistaken or delayed. Olfactory hallucinations
are a common accompaniment and useful diagnostic clue.
There is, in several series, an unexplained male predomin-
ance. Interictal memory impairment, specifically ALF and
AbA occur in the majority of patients, sometimes associ-
ated with a distinctive form of emotional lability. The
condition is most often of unknown aetiology, and such
cases have a benign prognosis. TEA occasionally occurs
as a result of structural pathology and as a manifestation
of auto-immune epilepsy. The aetiology of most cases of
the condition, the monthly occurrence of seizures in some
patients and the mechanisms and interrelationships of the
interictal features—amnestic and affective—all warrant
further study. The current report establishes TEA as an
important, treatable cause of memory loss in older peo-
ple, often mistaken for dementia, cerebrovascular disease
and functional amnesia.
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